5Haenel LC, Gordon BM, Sagel J. Radioiodine-induced thyrotoxicosis and thyroiditis after ablative therapy for papillary carcinoma:a case discussion and literature review [J]. Clin Nucl Med, 1999,24:741
4Robertson JS, Gorman CA. Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism[ J ]. J Nucl Med, 1976,17:826 - 835.
5McEvan AC.Absorbed dose in the marrow during 131I therapy[J].Brit J Radiol, 1977,50:329 - 331.
6Dobyns BM, Sheline GE, Workman JB, et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow- up study [J].J Clin Endocrinol Metab, 1974,38(6):976-998.
7Bermon M, Braverman LE, Burke J, et al. MIRD dose estimate report No.5[J] .J Nucl Med, 1975,16:857-860.
8Saenger EL, Thoma GE, Tompkins EA. Incidence of leukemia following treatment of hyperthyroidism [ J ]. JAMA, 1968,205 (12):855 - 862.
9Franklyn JA, Maisonneuve P, Sheppard M, et al . Cancer incidence and mortality after radioiodine treatment for hyperthyroidism:a population-based cohort study[J]. Lancet, 1999,353:2111-2115.
10Ghadban WK, Zirie MA. Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication[ J]. Saudi Med,2003,24(4) :347 - 351.
7Zhang Y, Jia S, Liu Y, et al. A clinical study of all-trans- retinoid-induced differentiation therapy of advanced thyroid cancer [J]. Nucl Med Commun, 2007, 28 (4): 251-255.
8Jemal A, Siegel R, Ward E, et al. Cancer statistics [J]. CA CancerJClin, 2006, 56 (2):106- 130.
9Reiners C, DietleinM, Luster M. Malignant goiter--thyroid cancer [J]. Dtsch Med Woehenschr. 2008, 133 (43): 2215- 2228.
10Johnson NA, Tublin ME. Postoperative surveillance of differentiated thyroid carcinoma: rationale, techniques, and controversies [J]. Radiology, 2008, 249 (2): 429-444.
